AstraZeneca (AZN) said Thursday a phase 3 trial of gefurulimab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis met primary and all secondary endpoints.
The company said the investigational drug demonstrated a "statistically significant and clinically meaningful" improvement from baseline in Myasthenia Gravis Activities of Daily Living total score at week 26 compared with placebo.
AstraZeneca said gefurulimab, a once-weekly self-administered subcutaneous C5 inhibitor, was well-tolerated and its safety profile was consistent with previous trials.
Shares of the company were up 2% in recent premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.